Cognitive-behavioural therapy (CBT) is effective in reducing distress in tinnitus patients. To make CBT more available, an Internet-based self-help treatment has been used since 1999 at the department of Audiology, Uppsala University hospital. After initial medical and psychological assessment the patients get access to the Internet treatment. The treatment programme is divided into six weeks, and each week the patient chooses treatment components, reads information and instructions, plans the training and then practises during one week. The patient prints out registration sheets and reports the progress at the web site, receiving E-mail feedback from the therapist. It is important to keep in contact with the patient. The efficacy of the treatment has been shown in two randomised controlled studies, showing significantly better result then a waiting-list control group and equal result compared to a CBT group treatment respectively. A recent replication showed that the results can be generalised to a clinical setting.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Importance: Delirium is common after cardiac surgery and associated with adverse outcomes. Intraoperative benzodiazepines may increase postoperative delirium but restricting intraoperative benzodiazepines has not yet been evaluated in a randomized trial.
Objective: To determine whether an institutional policy of restricted intraoperative benzodiazepine administration reduced the incidence of postoperative delirium.
Abdominal LIPUS Stimulation Prevents Cognitive Decline in Hind Limb Unloaded Mice by Regulating Gut Microbiota.
Mol Neurobiol
January 2025
Center for Biomedical Engineering, School of Information Science and Technology, Fudan University, Shanghai, 200433, China.
Weightlessness usually causes disruption of the gut microbiota and impairs cognitive function. There is a close connection between gut microbiota and neurological diseases. Low-intensity pulsed ultrasound (LIPUS) has a beneficial effect on reducing intestinal inflammation.
View Article and Find Full Text PDFBaricitinib Provides Significant Improvements in Quality of Life and Functioning in Adults with Moderate-to-Severe Atopic Dermatitis with Baseline Body Surface Area ≤ 40% and Severe Itch.
Dermatol Ther (Heidelb)
January 2025
Department of Dermatology, University of Tsukuba, Tsukuba, Japan.
Introduction: Patients with moderate-to-severe atopic dermatitis (AD), a body surface area (BSA) of ≤ 40%, and an itch numerical rating scale (NRS) score of ≥ 7 ("BARI itch dominant") have been characterized as an important group to consider for the oral janus kinase (JAK) 1/2 inhibitor baricitinib (BARI). Herein we aim to evaluate quality of life (QoL) and functioning outcomes in adult patients with BSA ≤ 40% and itch NRS ≥ 7 at baseline (BL) who received BARI 4 mg in the topical corticosteroid (TCS) combination trial BREEZE-AD7.
Materials: BREEZE-AD7 was a randomized, double-blind, placebo-controlled, parallel-group outpatient study involving adult patients with moderate-to-severe AD who received once-daily placebo or 2-mg or 4-mg BARI in combination with TCS for 16 weeks.
Oral and topical spironolactone in acne treatment: A meta-analysis of effectiveness and safety.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Faculty of Medicine, Cairo University, Cairo, Egypt.
Acne vulgaris (AV) is a common chronic inflammatory skin disorder that commonly lasts from adolescence to adulthood and has serious social and psychological consequences. Current treatments typically use antibacterial drugs, which contributes to the rise in antibacterial drug resistance. Spironolactone, a potassium-sparing diuretic with anti-androgen effects, has been used off-label to treat acne by lowering sebum production.
View Article and Find Full Text PDFBody Mass Index Did Not Impact Efficacy and Safety of Etrasimod: A Post Hoc Analysis of the ELEVATE UC Clinical Program.
Am J Gastroenterol
January 2025
Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
Objective: High body mass index (BMI) may reduce ulcerative colitis (UC) treatment efficacy. Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active UC. This post hoc analysis assessed treatment outcomes according to BMI in ELEVATE UC 52 and ELEVATE UC 12.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!